BroadOak Capital Partners (“BroadOak”), a life science focused investment and advisory firm, announced it has added over $200 million of permanent capital to its investing platform, a rare milestone that positions the firm to deploy patient, flexible capital across market cycles without the constraints of traditional fund structures and time horizons. The capital, which includes commitments from BroadOak principals and longtime strategic partner Research Corporation Technologies (RCT), dramatically enhances the firm’s capacity to provide strategic growth capital across healthcare infrastructure companies with a focus on life sciences tools, diagnostics, and biopharma services.
Read the full article: BroadOak Capital Partners Adds More Than $200M of Permanent Capital to Supplement Investment Platform //
Source: https://www.businesswire.com/news/home/20251028698252/en/BroadOak-Capital-Partners-Adds-More-Than-%24200-Million-of-Permanent-Capital-to-Supplement-Investment-Platform